In-vitro evaluation of dendrimeric formulation of oxaliplatin

References

• Battigelli A, Menard-Moyon C, Da Ros T, Prato M, Bianco A. 2013. Endowing carbon nanotubes with biological and biomedical properties by chemical modifications. Adv Drug Deliv Rev. 65(15):1899–1920.
   PubMed Web of Science ®Google Scholar
• Boyle P, Langman JS. 2000. ABC of colorectal cancer: epidemiology. BMJ. 321(7264):805–808.
   PubMed Web of Science ®Google Scholar
• Buczkowski A, Sekowski S, Grala A, Palecz D, Milowska K, Urbaniak P, Gabryelak T, Piekarski H, Palecz B. 2011. Interaction between PAMAM-NH2 G4 dendrimer and 5-fluorouracil in aqueous solution. Int J Pharm. 408(1–2):266–270.
   PubMedGoogle Scholar
• Cassidy J, Misset JL. 2002. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 29(5):11–20.
   PubMed Web of Science ®Google Scholar
• Chauhan AS, Jain NK, Diwan PV, Khopade AJ. 2004. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target. 12(9–10):575–583.
   PubMed Web of Science ®Google Scholar
• Chen CKJ, Kappen P, Hambley TW. 2019. The reduction of cis-platinum(iv) complexes by ascorbate and in whole human blood models using 1H NMR and XANES spectroscopy. Metallomics. 11(3):686–695.
   PubMed Web of Science ®Google Scholar
• Chen CK, Zhang JZ, Aitken JB, Hambley TW. 2013. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells. J Med Chem. 56(21):8757–8764.
   PubMed Web of Science ®Google Scholar
• Choudhary S, Gupta L, Rani S, Dave K, Gupta U. 2017. Impact of dendrimers on solubility of hydrophobic drug molecules. Front Pharmacol. 8:261.
   PubMed Web of Science ®Google Scholar
• Ciolkowski M, Rozanek M, Szewczyk M, Klajnert B, Bryszewska M. 2011. The influence of PAMAM-OH dendrimers on the activity of human erythrocytes ATPases. Biochim Biophys Acta. 1808(11):2714–2723.
   PubMed Web of Science ®Google Scholar
• Costa P. 2001. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm. 220(1–2):77–83.
   PubMedGoogle Scholar
• Culy CR, Clemett D, Wiseman LR. 2000. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 60(4):895–924.
   PubMed Web of Science ®Google Scholar
• Devarakonda B, Hill RA, Liebenberg W, Brits M, de Villiers MM. 2005. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm. 304(1–2):193–209.
   PubMedGoogle Scholar
• Devarakonda B, Otto DP, Judefeind AA, Hill RA, de Villiers MM. 2007. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm. 345(1–2):142–153.
   PubMed Web of Science ®Google Scholar
• Dutta RK, Sahu S. 2012. Development of oxaliplatin encapsulated in magnetic nanocarriers of pectin as a potential targeted drug delivery for cancer therapy. Results Pharma Sci. 2:38–45.
   PubMedGoogle Scholar
• Erturk AS, Gurbuz MU, Tulu M. 2017a. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil. Pharm Dev Technol. 22(1):111–121.
   PubMed Web of Science ®Google Scholar
• Erturk AS, Gurbuz MU, Tulu M. 2017b. New-generation Jeffamine (R) D230 core amine, TRIS and carboxyl-terminated PAMAM dendrimers: synthesis, characterization and the solubility application for a model NSAID drug Ibuprofen. Marmara Pharm J. 21(2):385–399.
   Google Scholar
• Fox LJ, Richardson RM, Briscoe WH. 2018. PAMAM dendrimer - cell membrane interactions. Adv Colloid Interface Sci. 257:1–18.
   PubMed Web of Science ®Google Scholar
• Gingras M, Raimundo JM, Chabre YM. 2007. Cleavable dendrimers. Angew Chem Int Ed Engl. 46(7):1010–1017.
   PubMed Web of Science ®Google Scholar
• Graf N, Lippard SJ. 2012. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev. 64(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Gu L, Wu ZH, Qi XL, He H, Ma XL, Chou XH, Wen XG, Zhang M, Jiao F. 2013. Polyamidomine dendrimers: an excellent drug carrier for improving the solubility and bioavailability of puerarin. Pharm Dev Technol. 18(5):1051–1057.
   PubMed Web of Science ®Google Scholar
• Gupta L, Sharma AK, Gothwal A, Khan MS, Khinchi MP, Qayum A, Singh SK, Gupta U. 2017. Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics. Int J Pharm. 528(1–2):88–99.
   PubMed Web of Science ®Google Scholar
• Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR. 2010. Advances in platinum chemotherapeutics. Chemistry. 16(24):7064–7077.
   PubMed Web of Science ®Google Scholar
• Henke H, Kryeziu K, Banfic J, Theiner S, Korner W, Bruggemann O, Berger W, Keppler BK, Heffeter P, Teasdale I. 2016. Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes. Macromol Biosci. 16(8):1239–1249.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Connors KA. 1965. Phase-solubility techniques. Adv Anal Chem Instr. 4:117–212.
   Google Scholar
• Höfer D, Galanski M, Keppler BK. 2017. Synthesis, Characterization, and Time-Dependent NMR Spectroscopy Studies of (SP-4-2)-[(trans-1R,2R/1S,2S-15N2)-Cyclohexane-1,2-diamine][(13C2)oxalato]platinum(II). Eur J Inorg Chem. 2017(17):2347–2354.
   Google Scholar
• Howell BA, Fan D, Rakesh L. 2006. Thermal decomposition of a generation 4.5 PAMAM dendrimer platinum drug conjugate. J Therm Anal Calorim. 85(1):17–20.
   Web of Science ®Google Scholar
• Hu J, Xu T, Cheng Y. 2012. NMR insights into dendrimer-based host-guest systems. Chem Rev. 112(7):3856–3891.
   PubMed Web of Science ®Google Scholar
• Huang X, Wu ZH, Gao W, Chen Q, Yu B. 2011. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin. Drug Dev Ind Pharm. 37(4):419–427.
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. 2004. FDA drug approval summaries: oxaliplatin. Oncologist. 9(1):8–12.
   PubMed Web of Science ®Google Scholar
• Igartua DE, Martinez CS, Temprana CF, Alonso SD, Prieto MJ. 2018. PAMAM dendrimers as a carbamazepine delivery system for neurodegenerative diseases: a biophysical and nanotoxicological characterization. Int J Pharm. 544(1):191–202.
   PubMedGoogle Scholar
• Jain K, Kesharwani P, Gupta U, Jain NK. 2010. Dendrimer toxicity: let’s meet the challenge. Int J Pharm. 394(1–2):122–142.
   PubMed Web of Science ®Google Scholar
• Kang SJ, Durairaj C, Kompella UB, O’Brien JM, Grossniklaus HE. 2009. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol. 127(8):1043–1047.
   PubMed Web of Science ®Google Scholar
• Khan MK, Nigavekar SS, Minc LD, Kariapper MS, Nair BM, Lesniak WG, Balogh LP. 2005. In vivo biodistribution of dendrimers and dendrimer nanocomposites - implications for cancer imaging and therapy. Technol Cancer Res Treat. 4(6):603–613.
   PubMed Web of Science ®Google Scholar
• Kiick KL. 2007. Materials science. Polymer therapeutics. Science. 317(5842):1182–1183.
   PubMedGoogle Scholar
• Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ. 2011. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem. 105(9):1115–1122.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Prajapati SK, Chauhan AS. 2011. Performance evaluation of PAMAM dendrimer based simvastatin formulations. Int J Pharm. 405(1–2):203–209.
   PubMedGoogle Scholar
• Kurtoglu YE, Mishra MK, Kannan S, Kannan RM. 2010. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int J Pharm. 384(1–2):189–194.
   PubMedGoogle Scholar
• Lao VV, Grady WM. 2011. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 8(12):686–700.
   PubMed Web of Science ®Google Scholar
• Levi F, Metzger G, Massari C, Milano G. 2000. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet. 38(1):1–21.
   PubMed Web of Science ®Google Scholar
• Li B, Meng Z, Li QQ, Huang XY, Kang ZY, Dong HJ, Chen JY, Sun J, Dong YS, Li J, et al. 2017. A pH responsive complexation-based drug delivery system for oxaliplatin. Chem Sci. 8(6):4458–4464.
   PubMed Web of Science ®Google Scholar
• Liang C, Wang H, Zhang M, Cheng W, Li Z, Nie J, Liu G, Lian D, Xie Z, Huang L, et al. 2018. Self-controlled release of Oxaliplatin prodrug from d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) functionalized mesoporous silica nanoparticles for cancer therapy. J Colloid Interface Sci. 525:1–10.
   PubMed Web of Science ®Google Scholar
• Liu X, Hao W, Lok CN, Wang YC, Zhang R, Wong KK. 2014. Dendrimer encapsulation enhances anti-inflammatory efficacy of silver nanoparticles. J Pediatr Surg. 49(12):1846–1851.
   PubMed Web of Science ®Google Scholar
• Ma J, Yang X, Hao W, Huang Z, Wang X, Wang PG. 2017. Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo. Eur J Med Chem. 128:45–55.
   PubMed Web of Science ®Google Scholar
• Matos BN, de Oliveira PM, Reis TA, Gratieri T, Cunha M, Gelfuso GM. 2015. Development and validation of a simple and selective analytical HPLC method for the quantification of oxaliplatin. J Chem-Ny. 2015:1–6.
   Web of Science ®Google Scholar
• Midgley R, Kerr D. 1999. Colorectal cancer. Lancet. 353(9150):391–399.
   PubMed Web of Science ®Google Scholar
• Moutinho C, Martinez-Cardus A, Santos C, Navarro-Perez V, Martinez-Balibrea E, Musulen E, Carmona FJ, Sartore-Bianchi A, Cassingena A, Siena S, et al. 2014. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J Natl Cancer Inst. 106(1):djt322.
   PubMedGoogle Scholar
• Nautiyal J, Kanwar SS, Yu Y, Majumdar AP. 2011. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal. 6:7.
   PubMedGoogle Scholar
• Nguyen DTD, Bach LG, Nguyen TH, Ho MH, Ho MN, Nguyen DH, Nguyen CK, Thi TTH. 2019. Preparation and characterization of oxaliplatin drug delivery vehicle based on PEGylated half-generation PAMAM dendrimer. J Polym Res. 26(5):116–130.
   Web of Science ®Google Scholar
• Nguyen TBT, Nguyen TTC, Tran HC, Nguyen CK, Tran NQ. 2015. 1H NMR spectroscopy as an effective method for predicting molecular weight of polyaminoamine dendrimers and their derivatives. Int J Polym Anal Charact. 20(1):57–68.
   Web of Science ®Google Scholar
• Nosova YN, Foteeva LS, Zenin IV, Fetisov TI, Kirsanov KI, Yakubovskaya MG, Antonenko TA, Viktor A, Tafeenko VA, Leonid A, et al. 2017. Enhancing the cytotoxic activity of anticancer PtIV complexes by introduction of lonidamine as an axial ligand. Eur J Inorg Chem. 2017(12):1785–1791.
   Google Scholar
• Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. 2013. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev. 65(13–14):1667–1685.
   PubMed Web of Science ®Google Scholar
• Pisani MJ, Wheate NJ, Keene FR, Aldrich-Wright JR, Collins JG. 2009. Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs. J Inorg Biochem. 103(3):373–380.
   PubMed Web of Science ®Google Scholar
• Raymond E, Chaney SG, Taamma A, Cvitkovic E. 1998. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 9(10):1053–1071.
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Woynarowski JM, Chaney SG. 1998. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 25(2):4–12.
   PubMed Web of Science ®Google Scholar
• Shadrack DM, Mubofu EB, Nyandoro SS. 2015. Synthesis of polyamidoamine dendrimer for encapsulating tetramethylscutellarein for potential bioactivity enhancement. Int J Mol Sci. 16(11):26363–26377.
   PubMed Web of Science ®Google Scholar
• Shao NM, Su YZ, Hu JJ, Zhang JH, Zhang HF, Cheng YY. 2011. Comparison of generation 3 polyamidoamine dendrimer and generation 4 polypropylenimine dendrimer on drug loading, complex structure, release behavior, and cytotoxicity. Int J Nanomedicine. 6:3361–3372.
   PubMed Web of Science ®Google Scholar
• Tokarczyk K, Jachimska B. 2019. Characterization of G4 PAMAM dendrimer complexes with 5-fluorouracil and their interactions with bovine serum albumin. Colloid Surface A. 561:357–363.
   Google Scholar
• Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. 1985. A new class of polymers: starburst-dendritic macromolecules. Polym J. 17(1):117–132.
   Web of Science ®Google Scholar
• van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV. 2013. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 65(10):1284–1298.
   PubMed Web of Science ®Google Scholar
• Vu MT, Bach LG, Nguyen DC, Ho MN, Nguyen NH, Tran NQ, Nguyen DH, Nguyen CK, Thi TTH. 2019. Modified carboxyl-terminated PAMAM dendrimers as great cytocompatible nano-based drug delivery system. Int J Mol Sci. 20(8):2016.
   Web of Science ®Google Scholar
• Wu L, Man C, Wang H, Lu X, Ma Q, Cai Y, Ma W. 2013. PEGylated multi-walled carbon nanotubes for encapsulation and sustained release of oxaliplatin. Pharm Res. 30(2):412–423.
   PubMed Web of Science ®Google Scholar
• Yang C, Fu ZX. 2014. Liposomal delivery and polyethylene glycol-liposomal oxaliplatin for the treatment of colorectal cancer (Review). Biomed Rep. 2(3):335–339.
   PubMedGoogle Scholar
• Yang H, Lopina ST. 2005. Extended release of a novel antidepressant, venlafaxine, based on anionic polyamidoamine dendrimers and poly(ethylene glycol)-containing semi-interpenetrating networks. J Biomed Mater Res A. 72(1):107–114.
   PubMedGoogle Scholar
• Yavuz B. 2014. In vitro/in vivo evaluation of dendrimeric systems for retinal drug delivery [PhD dissertation]. Ankara (Turkey): University of Hacettepe.
   Google Scholar
• Zhang D, Zhang JQ, Jiang KM, Li K, Cong YW, Pu SP, Jin Y, Lin J. 2016. Preparation, characterisation and antitumour activity of β-, γ- and HP-β-cyclodextrin inclusion complexes of oxaliplatin. Spectrochim Acta A Mol Biomol Spectrosc. 152:501–508.
   PubMed Web of Science ®Google Scholar